Table 2.
Clinical endpoints at 3-year follow-up
| 36 months follow-up | Ischaemic endpoint (n = 51) | Bleeding endpoint (n = 21) |
|---|---|---|
| Cardiac death, n (%) | 17 (33.3) | |
| Myocardial infarction, n (%) | 21 (41.2) | |
| Stroke, n (%) | 13 (25.5) | |
| Major bleeding, n (%) | 21 (100) |
Clinical endpoints at 3-year follow-up
| 36 months follow-up | Ischaemic endpoint (n = 51) | Bleeding endpoint (n = 21) |
|---|---|---|
| Cardiac death, n (%) | 17 (33.3) | |
| Myocardial infarction, n (%) | 21 (41.2) | |
| Stroke, n (%) | 13 (25.5) | |
| Major bleeding, n (%) | 21 (100) |